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Background: Folate plays a pivotal role in DNA synthesis, repair, methylation and homocysteine (Hcy) metabolism.
Therefore, alterations in the folate-mediated one-carbon metabolism may lead to abnormal methylation proliferation,
increases of tumor/neoplasia and vein thrombosis/cardiovascular risk. The serine hydroxymethyhransferase (SHMT),
methionine synthase (MS), methionine synthase reductase (MTRR) and cystathionine beta synthase (CBS) regulate key
reactions in the folate and Hcy metabolism. Therefore, we investigated whether the genetic variants of the SHMT, MS,
MTRR and CBS gene can affect plasma Hcy levels and are associated with breast cancer risk.
Methods: Genotyping was performed by PCR-RFLP method. Plasma Hcy levels were measured by the fluorescence
polarization immunoassay on samples of 96 cases and 85 controls.
Results: (a) The SHMT 1420 T, MS 2756G, MTRR 66G allele frequency distribution showed significant difference between
case and controls (p < 0.01 ~ 0.05). (b) The concentration of plasma Hcy levels of SHMT 1420TT was significantly lower
than that of the wild type, while the plasma Hcy levels of MS 2756GG, CBS 699TT/1080TT significantly higher than that
of the wild type both in case and controls. The plasma Hcy levels of MTRR 66GG was significantly higher than that of
wild type in cases. The plasma Hcy levels of the same genotype in cases were significantly higher than those of
controls except SHMT 1420CC, MS 2756AA, MTRR 66GG; (c) Multivariate Logistic regression analysis showed that SHMT
C1420T (OR = 0.527, 95% CI = 0.55 ~ 1.24), MS A2756G (OR = 2.32, 95% CI = 0.29 ~ 0.82), MTRR A66G (OR = 1.84, 95%
CI = 0.25 ~ 1.66) polymorphism is significantly associated with breast cancer risk. And elevated plasma Hcy levels were
significantly linked to increased risk of breast cancer (adjusted OR = 4.45, 95% CI = 1.89-6.24 for the highest tertile as
compared with the lowest tertile).
Conclusions: The current study results seem to suggest a possibility that SHMT C1420T mutation may be negatively
correlated with breast cancer susceptibility; while MS A2756G and MTRR A66G mutation may be positively associated
with breast cancer risk. SHMT C1420T, MS A2756G, MTRR A66G, CBS C1080T, CBS C699T locus mutation may be factors
affecting plasma levels of Hcy. The plasma Hcy levels could be metabolic risk factor for breast cancer risk to a
certain extent.
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About 1.2 million women suffer from breast cancer in the
world every year, and China is one of countries with most
rapid increase in incidence of the disease, which is already
up to 200,000 persons per year, c. 40,000 Chinese die of
the disease [1]. In this deadly disease, the mortality rate
approximately equals the incidence rate. The etiology of
breast cancer is poorly understood [2]. High-risk popula-
tions include those with a family history of breast cancer.
Several familial syndromes with known genetic defects
have been implicated, but they account for <6% of the
total cases [3]. The risk factors most consistently estab-
lished by epidemiologic studies are age, cigarette smoking,
alcoholism and estrogen level changing or hormone recep-
tor status [2,4,5]. Two prospective studies have since
shown that the increased risk of breast cancer associated
with low folate and high alcohol intake is limited to estro-
gen receptor-negative breast cancer [4,5].
Folate is critical to one-carbon metabolism, acting as a
coenzyme in facilitated novo deoxynucleoside triphos-
phate synthesis and to provide methyl groups required for
intracellular methylation reactions. Folate has generally
been thought to be safe and protective against anemia,
atherosclerosis, neural tube defects, adverse pregnancy
outcomes, neuropsychiatric disorders and cancer [6-8].
There is evidence that it can promote the growth of pre-
neoplastic lesions and recent work has emphasized the
importance of timing and dose of folate in the carcinogen-
esis process [9,10]. A large number of epidemiological
studies point to dietary folate, which is plentiful in vegeta-
bles and fruits, has been associated with reduced risk of
several cancers [11-14]. Several large prospective epi-
demiological studies have suggested an importance of fol-
ate in reducing breast cancer risk, particularly among
women who regularly consume alcohol [15,16].
Homocysteine (Hcy) is a non-protein-forming, sulfur
containing amino acid, formed exclusively by demethyla-
tion of methionine and degraded by remethylation or
transsulfuration [17]. Hcy plasma levels are influenced by
genetic polymorphisms of key enzymes involved in folate
and methionine metabolism. Recent studies have shown
that low folate status, with hyperhomocysteinemia as a
consequence, is associated with oncogenic risk in patients
with inflammatory bowel disease [18], probably due to hy-
pomethylation [19]. Aberrant methylation of DNA is fre-
quently found in tumor cells [20]. Global hypomethylation
can result in chromosome instability [21], whereas region-
specific hypermethylation has been associated with the in-
activation of tumor suppressor genes [22].
Hcy is an immediate precursor for the biosynthesis of
influences S-adenosylhomocysteine (SAH) and hyperho-
mocysteinemia results in impaired balance between me-
thionine, S-adenosylmethionine (SAM), and SAH. This
imbalance may lead to changes in methyl-donor substratelevels and consequently to a modulation of DNA methyla-
tion pattern [23]. Hcy is also a potent inhibitor of DNA
hydroxymethyltransferase being SAH inhibits DNA hydro-
xymethyltransferase. Additional Hcy is converted to SAH
pathway may involve folate-dependent reactions leading to
changes in the availability of nucleotides, such as thymidy-
late, for DNA synthesis and repair [24]. This mechanistic
hypothesis suggests that hyperhomocysteinemia exerts its
pathogenic effects largely through metabolic accumulation
of intracellular SAH, a strong non-competitive inhibitor of
the catechol-O-methyltransferase (COMT)-mediated me-
thylation metabolism of endogenous and exogenous cate-
chols (including 2-OH-E2 and 4-OH-E2) [19,20]. The
oxidation of endogenous catechols generates large amounts
of chemically reactive products, (such as quinone/semi-
quinone intermediates) that are highly toxic to surrounding
cells [21]. A strong inhibition of the methylation metabol-
ism of 2-OH-E2 would significantly decrease the formation
of 2-MeO-E2 (an endogenous anticarcinogenic metabolite
of E2) and an inhibition of the methylation of 4-OH-E2
would lead to accumulation of this hormonally active and
strongly procarcinogenic estrogen metabolite [22]. Both of
these effects resulting from the inhibition of the methyla-
tion metabolism of catechol estrogens would facilitate the
development of estrogen-dependent carcinogenesis in the
target organs.
For all these reasons, hyperhomocysteinemia has been
regarded as a risk factor for cancer and Hcy levels have
been proposed as a new tumor marker since they not
only accurately reflect the proliferation rates of tumor
cells but also respond to tumor cell death [25].
Serine hydroxymethyltransferase (SHMT), methionine
synthase (MS), methionine synthase reductase (MTRR)
and cystathionine beta synthase (CBS) are genes that en-
code enzymes involved in the folate and Hcy metabolic
pathway, which are critical in the DNA synthesis, methyla-
tion process and Hcy metabolism (Figure 1) [26]. Studies
have suggested that polymorphisms in these genes may be
related to plasma Hcy levels increasing and cancer devel-
opment [27-29], but the study on interaction between
plasma Hcy levels, above-mentioned genetic polymor-
phisms in folate pathway and breast Cancer susceptibility
is still lacking. Thus the aim of this study was to analyze
the possible associations between Hcy concentration in
serum, polymorphisms of enzymes involved in folate/me-
thionine metabolism and breast cancer susceptibility. This
knowledge is important for enhancing our understanding
and improving the effectiveness of our public health rec-
ommendations Figure 1.
Methods
Case and control selection
Eligible patients with breast cancer were randomly se-
lected from 2010 January to 2011 April in the Third
Figure 1 Overview of the folate-methionine metabolic pathway investigated in this study. THF, tetrahydrofolate; DHF, dihydrofolate; 5,
10-CH2 THF, 5,10-methylenetetrahydrofolate; 5-Methyl THF, 5-methyl tetrahydrofolate; dUMP deoxyuridine monophoshate; dTMP, deoxythymidine
monophoshate; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; SHMT, serine hydroxymethyhransferase; MS, methionine synthase;
MTRR, methionine synthase reductase; CBS, cystathionine beta synthase; B6, vitamin B6; Ser, serine and Gly, glycine.
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hospital of Yunnan province), Yunnan, China. Based on
the hospital chart number, cases involved 96 women con-
secutively selected from subjects with a first confirmed his-
topathologic diagnosis of breast carcinoma in the age
range of 30–77 years. The each types of cancers including
infiltrating ductal carcinoma (15 individuals), papillary car-
cinoma (11 individuals), invasive ductal intraductal carcin-
oma (40 individuals), smooth cribriform carcinoma (10
individuals), medullary carcinoma (8 individuals), fibrosar-
coma (3 individuals), non invasive ductal intraductal car-
cinoma (4 individuals) and accessory breast malignant
tumor (5 individuals). Eighty-five Control subjects com-
prising individuals without a history of cancer in the age
range of 18–76 years were simultaneously recruited form
the health examination clinics of same hospital during the
same study period. Eventually, the controls were individu-
ally matched for age (±3 years) and menopausal status
(premenopause or postmenopause) to cases with a 1: 1
case–control ratio.
Collection of questionnaire data and blood specimens
Approval for the present study was obtained from the
National Natural Sciences Foundation of China (NSFC)
and the Yunnan Scientific and Technological Commit-
tee. Once case patients and control subjects agree toparticipate, written informed consent was obtained from
all subjects. Pathology tests were performed and the
number of active manifestations recorded for each pa-
tient. The pathology tests included morphological patho-
logical examination of breast, nipple discharge cytology,
cytological smear, biopsy, endoscopic examination and
so on. Data were collected on sociodemographic charac-
teristics, menstrual and reproductive history, meno-
pausal status, lifestyle behaviors and medical history as
well as family history of breast and other cancers. More
specifically, in this study, menopausal status was defined
as last menstruation after one year free of menstrual
cycle and no attempt was made to distinguish between
women with artificial and those with natural menopause.
Subjects taking vitamin supplements in the previous
6 months were excluded from the study.
Measurement of plasma levels of Hcy
Plasma Hcy concentrations (ie., plasma total Hcy mea-
sured as the sum of all Hcy subfractions in plasma in-
cluding free and protein-bound forms) were determined
by fluorescence polarization immunoassay (FPIA) tech-
nique (Axis Biochemicals, ASA, Oslo, Norway). FPIA
was run on an IMx analyzer (Abbott, Ill, USA). The 95%
confidence interval of plasma Hcy level suggested by the
manufacturer for healthy individuals is 4.45–12.42
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gauge needle from a peripheral vein, avoiding haemolysis
in the morning hours after an overnight fasting and 30 mi-
nutes of supine rest and collected into 10 mL empty evac-
uated tubes without EDTA, heparin, or clot activators.
Samples were centrifuged at 1000 × g for 10 minutes. The
plasma was separated in aliquots and immediately frozen
and stored at −80°C within 60 minutes until use.
Genotyping of the SHMT C1420T, CBS C699T/C1080T, MS
A2756G, MTRR A66G polymorphisms determination
Genomic DNA was extracted from peripheral leukocytes
isolated from acid-citrate-dextrose-anti-coagulated blood
using a commercially available FlexiGen DNA isolation
kit (Qiagen, Valencia CA).
The polymorphisms MS A2756G were determined by
polymerase chain reaction (PCR) followed by restriction
fragment length polymorphisms (RFLP) [30]. The ampli-
fied fragments of MS A2756G polymorphisms were
digested with restriction enzymes, HaeIII (Beijing Bio-
logical Engineering Co. Ltd., China). MTRR A66G geno-
type was analyzed by PCR followed by RFLP as described
by Scazzone et al. [28]. The amplified DNA fragment was
digested with NdeI (Beijing Biological Engineering Co.
Ltd., China). The polymorphisms T1080C and C699T in
CBS gene were determined using PCR-RFLP based assays
using restriction enzymes BstUI (Beijing Biological Engin-
eering Co. Ltd., China) for T1080C and RsaI (Beijing Bio-
logical Engineering Co. Ltd., China) for C699T [31,32].
About 10% of the samples were reexamined by an investi-
gator who had not attended the previous collection of
data. There were no discrepancies in the results.To de-
termine the SHMT C1420T polymorphism an allele dis-
crimination method using fluorogenic 3′-minor groove
binding (MGB) probes described by Skibola et al. was
adapted [33]. The real-time PCR was performed in Rotor-
gene 2000 real-time cycler (Corbette Research, Mortlake,
Australia). About 10% of the samples were parallel geno-
typed by real-time PCR and PCR-RFLP method using
Eam1104I restriction enzyme (Fermentas Inc., Hanover,
MD, USA). The discrepancy between the methods was
below 1%. All products were electrophoresed at room
temperature for 7 h at 300 volts on a 8% polyacrylamide
gel (2% C) containing 5% glycerol and silver stained.
Genotypes of MS A2756G, MTRR A66G, CBS C1080T/
C699T, SHMT C1420T were defined as 2756AA/66AA/
1080CC/699CC/1420CC (ancestral homozygous) also repor-
ted in the literature as wild homozygous, 2756AG/66AG/
1080CT/699CT/1420CT (mutant heterozygous) and 2756GG/
66GG/1080TT/699TT/1420TT (mutant homozygous).
Statistical analysis
Descriptive statistics were calculated to compare effect-
iveness of matching variables (age) and to assess breastcancer risk factor information. Crude odds ratios, t-tests
and chi-square tests were examined to determine which
variables were statistically significant associated with
breast cancer risk. Covariates that did not change the ef-
fect estimate of fungicides on breast cancer risk by more
than 10% were not included in the final logistic regression
model. As cases and controls in this study were frequency
matched, the analysis utilized unconditional logistic re-
gression and included the matching variables. The results
are given as odds ratio (OR) with 95% confidence interval
(95% CI) were estimated using age-matched conditional
logistic models adjusted for potential confounders. Trends
in the OR (gene dosage effect) were calculated by assign-
ing ordinal values to the genotypes. A non-parametric test
for trend was used to look for differences in Hcy levels by
genotype. For each polymorphism, deviation from Hardy–
Weinberg equilibrium for the genotype distribution was
evaluated in controls only, using an exact test. All geno-
types were found to be in Hardy–Weinberg equilibrium.
All analyses were performed using STATA 10.1 (College
Park, TX) and the Statistical Package for Social Sciences
(SPSS) version 15.
Results and discussion
Characteristics of case and controls
Table 1 showed the study population consisted of 96 breast
cancer cases and 85 controls with a mean (±SD) age of
47.83 (±10.9) years and 45.22 (±11.8) years, respectively.
There were no significant differences between cases and
controls in terms of age at menarche (12.7 ± 1.2 years vs.
13.8 ± 1.4 years), age at first full-term pregnancy (28.4 ±
6.4 years vs. 25.9 ± 3.8 years), and age at menopause (50.7 ±
7.9 years vs. 52.5 ± 6.6 years). No significant differences
were found between cases and controls in terms of the pro-
portions of women with alcohol drinking (10.4% vs. 4.7%),
post-menopausal women (28.1% vs. 24.7%). Smokers were
no significantly more common in cases than in controls
(14.6% vs. 0%).
Effect of plasma Hcy levels on risk of breast cancer
Table 2 presents high plasma Hcy was statistically sig-
nificantly associated with increased risk of breast cancer
in the analysis controlling for age at enrollment and dur-
ation of fasting; the OR comparing the highest with the
lowest tertile of plasma Hcy was 4.45 (95% CI = 1.89–
6.24). To explore possible modifying effect on the associ-
ation between plasma Hcy concentrations and breast
cancer risk by menopausal status, Table 3 shows stratifi-
cation by menopausal status in the association between
plasma Hcy levels and breast cancer risk.
Analysis of gene polymorphisms and risk of breast cancer
For polymorphisms of SHMT 1420T, MS 2756G, MTRR
66G allele are observed in Figures 2, 3, 4, 5 and 6, and
Table 1 Characteristics of case and controls
Cases
(n = 96) n (%)
Controls


















Never 76(79.2) 85(100) <0.01
Formera 14(14.6) 0(0) <0.01












Unknown 5(5.21) 1(1.04) 0.11
Family history of breast cancer
Yes 0(0) 0(0)
No 96(100) 85(100)
Unknown 0(100) 0(100) 1.00
Menopausal status
Premenopausal 69(71.9) 64(75.3)





Unknown 4(4.16) 2(2.35) 0.82





Unknown 1(1.04) 2(2.35) 0.91
Others 2(2.08) 1(1.17) 0.21
SD, standard deviation; BMI, body mass index.
aFormer smokers and drinkers were defined as subject who had quit smoking
and drinking at at least 1 year previously.
bModerate drinker <5 days per week.
cHeavy drinker ≥5 days per week.
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CT and TT genotypes were 37.6%, 42.4%, 20%, C and T
allele frequencies were 58.8%, 41.2% in control group,
while SHMT 1420CC, CT and TT genotypes were 50%,
40.6%, 9.4%, C and T allele frequencies were 70.3%, 29.7%
in case group. SHMT C1420T polymorphism of T allele
frequency in case group was significantly lower than that
in control group (p = 0.039). SHMT 1420CT and SHMT
1420TT genotypes can reduce the risk of breast cancer by
1.25 times and 2.5 times compared with SHMT 1420CC.
The odds ratio between SHMT 1420CT/TT/CT+TT and
breast cancer risk was observed to be 0.828 (95%
CI = 0.54 ~ 1.27, p = 0.388) vs. 0.422 (95% CI = 0.40 ~ 1.71,
p = 0.021) vs. 0.527 (95% CI = 0.55 ~ 1.24, p = 0.036)
Figures 2, 3, 4, 5 and 6.
MS 2756AA, AG and GG genotypes were 81.2%,
15.3%, 3.5%, A and G allele frequencies were 88.9%,
11.1% in control group, while MS 2756AA, AG and GG
genotypes were 61.4%, 36.4%, 2.2%, A and G allele fre-
quencies were 79.7%, 20.3% in case group. MS A2756G
polymorphism of G allele frequency in case group was
significantly higher than that in control group (p =
0.004). The odds ratio between MS 2756AG/GG/AG +
GG and breast cancer risk was observed to be 2.49 (95%
CI = 0.29 ~ 0.833, p = 0.009) vs. 1.72 (95% CI = 0.13 ~
2.11, p = 0.36) vs. 2.32 (95% CI = 0.29 ~ 0.82, p = 0.006).Table 2 Risk of breast cancer associated with plasma
homocysteine (Hcy) concentration
Variablea,b Cases
(n = 96) n (%)
Controls





<7.26 16(16.7) 28(32.9) 1.00(reference)
7.26–11.56 11(11.4) 30(35.3) 0.64(0.23–1.12)
>11.56 69(71.9) 27(31.8) 4.45(1.89–6.24)
aThe total number of cases and controls does not correspond because of
missing data.
bVariables were categorized based on the tertile distribution among
control subjects.
cOR, odd ratio; CI, confidence interval.
cAdjustment for age at enrollment and duration of fasting.
Table 3 Odds ratio (OR) and 95% confidence interval (CI)
of breast cancer by the tertile distribution of plasma
total homocysteine, with stratification according to
menopausal status
Stratified variablea,b Plasma total Hcy (μ mol/L)
1st 2nd 3rd p
Menopausal status
Pre-menopausal <0.001
Cases/controls 8/20 4/19 57/25
ORc (95% CIc) 1.0(reference) 0.53(0.2-1.1) 5.7(2.7-8.8)
Post-menopausal <0.001
Cases/controls 8/8 7/11 12/2
ORc (95% CIc) 1.0(reference) 0.64(0.2-1.5) 6(3.1-8.2)
aThe total number of cases and controls does not correspond because of
missing data.
bVariables were categorized based on the tertile distribution among
control subjects.
cOR, odd ratio; CI, confidence interval.
cAdjustment for age at enrollment and duration of fasting.
Figure 3 Genotyping of the MS A2756G polymorphisms.
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88.2%, 1.2%, A and G allele frequencies were 74.1%,
25.9% in control group, while MTRR 66AA, AG and GG
genotypes were 13.5%, 82.3%, 4.2%, A and G allele fre-
quencies were 54.7%, 45.3% in case group. MTRR A66G
polymorphism of G allele frequency in case group was
significantly higher than that in control group (p =
0.007). The odds ratio between MTRR 66AG/GG/ AG +
GG and breast cancer risk was observed to be 1.17 (95%
CI = 0.26 ~ 2.23, p = 0.51) vs. 2.61 (95% CI = 0.30 ~
1.18, p = 0.03) vs. 1.84 (95% CI = 0.25 ~ 1.66, p = 0.047)
(Tables 3 and 4).
CBS 1080CC, CT and TT genotypes were 42.4%, 43.5%,
14.1%, C and T allele frequencies were 64.1%, 35.9% in
control group, while CBS 1080CC, CT and TT genotypes
were 49%, 37.5%, 13.5%, C and T allele frequencies wereFigure 2 Genotyping of the SHMT C1420T polymorphisms.67.7%, 32.3% in case group. There was no significantly
different in CBS C1080T polymorphism of T allele fre-
quency between case and control group. The odds ratio
between CBS 1080CT/TT/ CT + TT and breast cancer
risk was observed to be 1.31 (95% CI = 0.21 ~ 1.80, p =
0.86) vs. 1.04 (95% CI = 0.42 ~ 2.27, p = 0.90) vs. 1.15
(95% CI = 0.69 ~ 3.11, p = 0.85).
CBS 699CC, CT and TT genotypes were 40.0%, 44.7%,
15.3%, C and T allele frequencies were 62.4%, 37.6% in
control group, while CBS 699CC, CT and TT genotypes
were 49.0%, 37.5%, 13.5%, C and T allele frequencies
were 67.7%, 32.3% in case group. There was no signifi-
cantly different in CBS C699T polymorphism of T allele
frequency between case and control group. The oddsFigure 4 Genotyping of the MTRR A66G polymorphisms.
Figure 5 Genotyping of the CBS C699T polymorphisms.
Table 4 Genotype frequencies, allele frequencies at SHMT








Mutation Allelic frequency pa
Cases (%) Controls (%)




















a*Different from reference (p < 0.05), **different from reference (p < 0.01).
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cancer risk was observed to be 1.27 (95% CI = 0.66 ~ 2.54,
p = 0.69) vs. 1.14 (95% CI = 0.38 ~ 1.83, p = 0.73) vs. 1.20
(95% CI = 0.45 ~ 1.65, p = 0.82).
Hcy levels in different gene polymorphisms
Table 6 shows the plasma Hcy level of SHMT 1420TT
homozygous were significantly lower than those of wild
type CC in cases and controls [(14.86 ± 6.06) vs. (16.44 ±
17.69) μ mol/L in cases, p < 0.05; (10.02 ± 2.97) vs. (14.99 ±
7.12 μ mol/L in controls, p < 0.05]; plasma Hcy level ofFigure 6 Genotyping of the CBS C1080T polymorphisms.MS 2756GG genotype was significantly higher than that of
wild type AA in cases and controls [(21.15 ± 23.30) vs.
(12.23 ± 5.16) μ mol/L in cases, p < 0.001; (19.97 ± 12.88)
vs. (10.71 ± 3.30) μ mol/L in controls, p < 0.01]; plasma
Hcy level of MTRR 66GG homozygote genotype was sig-
nificantly higher than that of wild type AA in cases
[(23.70 ± 23.51) vs. (17.52 ± 5.69) μ mol/L, p < 0.05], Due
to GG gene was only one in controls, there was no signifi-
cant difference between three kinds of genotypes; plasma
Hcy levels of CBS 699TT genotype was significantly higher
than of wild type CC in cases and controls (19.52 ± 15.89)
vs. (14.47 ± 3.32) μ mol/L in cases, p < 0.01; (15.47 ± 6.82)
vs. (10.36 ± 5.12) μ mol/L in controls, p < 0.01]; plasma
Hcy levels of CBS 1080TT genotype was significantly
higher than that of wild type CC in cases and con-
trols [(20.99 ± 16.89) vs. (15.76 ± 7.17) μ mol/L in cases,
p < 0.01; (16.45 ± 9.45) vs. (9.28 ± 3.30) μ mol/L in con-
trols, p < 0.001].
Comparison of plasma Hcy levels between case and
controls with identical genotype
As shown in Table 6, plasma Hcy levels of SHMT
1420CT/TT, CBS 699CC/CT/TT, CBS 1080CC/CT/TT,
Table 5 Odd rations (OR) and 95% CI for SHMT C1420T,
CBS C699T,CBS C1080T,MS A2756G and MTRR A66G
polymorphisms with risk of breast cancer
Genotype Cases n (%) Controls n (%) ORa (95% CIa) pb
SHMT 1420CC 48(50.0) 32(37.6) 1.0 (Reference)
SHMT 1420CT 39(40.6) 36(42.4) 0.828(0.54 to 1.27) 0.388
SHMT 1420TT 9(9.40) 17(20) 0.422(0.40 to 1.71) 0.021*
SHMT 1420CT/TT 48(50.0) 53(62.4) 0.527(0.55 to 1.24) 0.036*
CBS 699CC 38(39.6) 36(42.4) 1.0 (Reference)
CBS 699CT 44(45.8) 37(43.5) 1.10(0.66 to 2.54) 0.69
CBS 699TT 14(14.6) 12(14.1) 1.14(0.38 to 1.83) 0.73
CBS 699CT/TT 58(60.4) 49(57.6) 1.27(0.45 to 1.65) 0.82
CBS 1080CC 47(49.0) 34(40.0) 1.0 (Reference)
CBS 1080CT 36(37.5) 38(44.7) 1.0 (Reference) 0.86
CBS 1080TT 13(13.5) 13(15.3) 1.04(0.42 to 2.27) 0.90
CBS 1080CT/TT 49(51.0) 51(60) 1.15(0.69 to 3.11) 0.85
MS 2756AA 59(61.4) 61(71.8) 1.0 (Reference)
MS 2756AG 35(36.4) 21(24.7) 2.49(0.29 to 0.833) 0.009**
MS 2756GG 2(2.2) 3(3.5) 1.72(0.13 to 2.11) 0.36
MS 2756AG/GG 37(38.5) 24(28.2) 2.32(0.29 to 0.82) 0.006**
MTRR 66AA 13(13.5) 9(10.6) 1.0 (Reference)
MTRR 66AG 79(82.3) 75(88.2) 1.17(0.26 to 2.23) 0.51
MTRR 66GG 4(4.17) 1(1.18) 2.61(0.30 to 1.18) 0.03*
MTRR 66AG/GG 83(86.5) 76(89.4) 1.84(0.25 to 1.66) 0.047*
aOR, odd ratio; CI, confidence interval.
aAdjustment for age at enrollment and duration of fasting.
b*different from reference (p < 0.05), **different from reference (p < 0.01).
Table 6 The effect of SHMT C1420T,CBS C699T,CBS
C1080T,MSA2756G,MTRR A66G polymorphic genotype on
Hcy concentration
Genotype Plasma total Hcy(μ mol/L)a pb
Cases Controls
SHMT 1420CC 16.44 ± 17.69 14.99 ± 7.12 0.15
SHMT 1420CT 18.74 ± 12.32 11.04 ± 4.64 0.01**
SHMT 1420TT 14.86 ± 6.06 10.02 ± 2.97 0.014*
p = 0.021*(TT&CC) p = 0.033*(TT&CC)
CBS 699CC 14.47 ± 3.32 10.36 ± 5.12 0.01**
CBS 699CT 21.62 ± 13.08 11.20 ± 3.56 0.011*
CBS 699TT 19.52 ± 15.89 15.47 ± 6.82 0.019*
p = 0.01**(TT&CC) p = 0.028**(TT&CC)
CBS 1080CC 15.76 ± 7.17 9.28 ± 3.30 0.01**
CBS 1080CT 16.64 ± 10.95 11.67 ± 2.36 0.021*
CBS 1080TT 20.99 ± 16.89 16.45 ± 9.45 0.01**
p = 0.01**(TT&CC) p = 0.01**(TT&CC)
MS 2756AA 12.23 ± 5.16 10.71 ± 3.30 0.121
MS 2756AG 20.43 ± 15.32 13.39 ± 7.91 0.01**
MS 2756GG 21.15 ± 23.30 19.97 ± 12.88 0.042*
p = 0.01**(GG&AA) p = 0.002**(GG&AA)
MTRR 66AA 17.52 ± 5.69 10.88 ± 2.67 0.01**
MTRR 66AG 15.83 ± 10.99 12.67 ± 5.13 0.040*
MTRR 66GG 23.70 ± 23.51 22.20
p = 0.031*(GG&AA)
aValues are expressed as mean ± SD.
b*p < 0.05, **p < 0.01 compared with wild genotype.
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nificantly higher than those in the controls (p < 0.001 ~ 0.01).
The results of the present study of associations be-
tween one-carbon metabolism-related gene polymor-
phisms or plasma Hcy levels and breast cancer risk
suggested that (i) SHMT 1420TT genotype is inversely
associated with breast cancer risk; (ii) the MS 2756GG
or MTRR A66G genotype is positively associated with
breast cancer risk; (iii) SHMT 1420CC, MS 2756GG,
MTRR 66GG, CBS 1080TT, CBS 699TT genotype may
be a factor in reducing plasma Hcy levels, and (iv)
plasma Hcy level is positively associated with breast
cancer risk.
Many observational studies have highlighted the im-
portance of adequate folate intake in breast cancer pre-
vention, as reviewed in a recent meta-analysis, but the
results were inconsistent [34]. Almost all studies were
conducted in predominantly USA populations, where
fortification of folic acid intake with supplements causes
difficulty in the evaluation of folate consumption [35].
On the other hand, folate intake in China is almost
exclusively from natural sources, mainly from plant
sources such as vegetables, with spinach making the
highest contribution followed by rice and green tea[36]. However, few studies in Asia including China have
investigated associations between folate intake and breast
cancer risk [37] and further investigations in various popu-
lations are clearly warranted.
The folate metabolism pathway is complex and involves
various enzymes that regulate DNA synthesis and DNA
methylation. Among others, SHMT catalyzes the reversible
conversion of serine and tetrahydrofolate to glycine and
methylene tetrahydrofolate; MS supports methionine home-
ostasis by catalyzing the remethylation of homocysteine to
methionine in a cobalamine-dependent reaction that utilizes
5,10-methylenetetrahydrofolate reductase (MTHFR) as me-
thyl donor [26,38]; and MTRR is responsible for keeping
MS in an active form by maintaining adequate levels of acti-
vated cobalamin, the enzyme cofactor for MS. Polymor-
phisms in the genes that encode these enzymes may modify
the effect of folate on breast cancer.
Our results showed individuals with the SHMT 1420TT
genotype were lower at risk of breast cancer, consistent
with previous studies [39,40]. This is reasonable because
enzyme activity with the SHMT 1420CC genotype is lower
and thus less folate is available for DNA methylation. Our
study also showed a significant interaction between the
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TheMS 2756GG and MTRR 66GG genotype increases the
risk among Chinese women in the present study. While
functional effects have yet to be fully established, the G al-
lele of MS and MTRR are considered to decrease the en-
zyme activity compared with the A allele [41,42]. Subjects
with MS 2756GG or MTRR 66GG may have reduced me-
thionine levels compared with those who had other geno-
types and therefore our finding of increased breast cancer
risk is plausible. In our study, SHMT 1420 CC genotype
carriers were found to have increased plasma Hcy levels
compared to TT carriers. For the MS 2756 A→G poly-
morphism, decreased Hcy levels have been found for the
GG genotype as compared to the AA genotype. For MTRR
A66G elevated Hcy levels for carriers of the homozygote
wild-type genotype (AA) as compared to other genotypes.
However, the results in this study may have occurred by
chance due to small size of SHMT 1420TT, MS 2756 GG
and MTRR GG genotype and information on SHMT, MS
and MTRR polymorphisms and breast cancer is scarce, thus
further investigations are needed.
The gene CBS, located on chromosome 21q22.3, en-
codes an important enzyme involved in transulfuration of
Hcy produced during methyl-group metabolism [43]. Not-
ably, CBS deficiency causes increased plasma methionine
levels and decreased cysteine levels [44] which in turn are
known to correlate with homocystinuria, cardiovascular
disease and hepatocellular carcinoma [45,46]. The transul-
furation pathway links methionine metabolism to the bio-
synthesis of cellular redox controlling molecules such as
cysteine, glutathione, and taurine [47]. Cysteine generated
through the transulfuration pathway determines cellular
redox-controlling molecule levels, such as glutathione and
taurine protecting cells against reactive species-induced
damage [48] of DNA through base and sugar modifica-
tions, base-free sites, DNA-protein crosslinks, and strand
breaks [49,50]. Thus, downregulated expression of CBS
may impair the production of glutathione thus facilitating
tumorigenesis [51]. In addition, redox imbalance stimu-
lates protein kinase and poly-(ADP ribosylation) pathways
leading to inhibition of apoptosis and resulting in necrotic
cell death, followed by inflammatory responses and tumor
development [52]. There are some studies that have evalu-
ated the association between malignant tumor susceptibil-
ity and polymorphisms of the CBS gene (844ins68) in
colorectal cancer [53,54] but not in esophageal or gastric
cancer [55]. In addition, CBS 844ins68 polymorphism is
associated with decreased survival in head and neck squa-
mous cell cancer [56]. In the present study, no association
between the breast cancer patients and the CBS 699/1080
alleles or genotypes was identified. These results corrobo-
rated recent findings of a lack of association, especially for
the TT genotype of the CBS gene, with increased cancer
risk. Furthermore, our results showed CBS C699T/C1080T polymorphisms can remarkably increase plasma
Hcy level, suggested CBS 699 or 1080 mutation maybe
make the loss of CBS expression lead to the accumulation
of Hcy, which will be recycled to methionine by MS via
the remethylation pathway [57]. As methionine acts as the
source of methyl group donor for DNA methylation, its
increase caused by loss of CBS expression may dysregulate
DNA methylation.
There are evidence for a role of Hcy in pathogenesis of
cardiovascular diseases [18], renal failure [21] pregnancy
complication [22], psychiatric and neurodegenerative dis-
orders [24]. The Association between Hcy and breast can-
cer risk is unclear. In our study, we observed higher
plasma Hcy levels in the breast cancer group, in accord-
ance with some observation [25,58]. It was also shown that
genetic variation in folate metabolism and inceased
plasma Hcy levels was associated with an increased risk of
breast cancer. Furthermore, a similar pattern of enhanced
risk of breast cancer at higher plasma Hcy levels was ob-
served in both pre-menopausal and post-menopausal
women. This study seems to support the previously sug-
gested role of Hcy as a potential tumor marker [43]. Hcy
itself is toxic to human cells via its highly reactive lactone
form which is incorporated into protein by methionyl-
tRNA synthase [16]. Oxidation of thiol-containing amino
acids produces free radicals having damaging effects on
DNA [14], and their prooxidant effects have been impli-
cated in DNA damage [21]. Decreased glutathione levels
in some study indicate increased detoxification against
oxidative stress in carcinogenesis. Indeed, a hypothesis for
hyperhomocysteinemia as a risk factor for estrogen in-
duced tumorigenesis has been proposed by Zhu [59].
Namely, elevated concentrations of Hcy exert pathogenic
effects largely through metabolic accumulation of intracel-
lular SAH, a strong non-competitive inhibitor of the
COMT-mediated methylation metabolism of endogenous
and exogenous catechols (including 2-OH-E2 and 4-OH-
E2) [60]. It is well-known that the oxidative metabolites of
estrogens, including the catechol estrogens (2-OH-E2/E1
and 4-OH-E2/E1) and 16a-OHE1, contribute to estrogen-
induced tumors in certain animal models and to the devel-
opment of human breast cancer [20,34,46]. The principal
pathway for inactivation of catechol estrogens is O-
methylation by COMT [22]. Accordingly, determination
of Hcy levels is also important for protection from its toxic
effects and for choosing therapy. Because Hcy is converted
to SAH which is a potent inhibitor of DNA methyltrans-
ferase, so DNA methyltransferase activity and DNA
methylation status should be taken into consideration in
future.
Conclusions
In summary, we have shown a significant association
among MS, MTRR, SHMT, CBS polymorphisms, elevated
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More research is needed regarding the functional effects
of polymorphisms in these genes as related to effects on
folate metabolism and subsequent folate availability and
large populations are required to examine these gene-gene
and gene-nutrient interactions using traditional epidemio-
logic methods. New methods of mathematical modeling
developed for this pathway may provide insight into the
effects of modifying components of the system to inform
future studies. Additional studies are needed to replicate
our findings in different racial/ ethnic groups and improve
our ability to predict the effects of polymorphisms within
genes in one-carbon metabolism and folate status. Future
studies are needed to prove causality and provide insight
on the mechanism of action of Hcy in breast tumorigen-
esis. In the study, there is big difference between the mini-
mum age of cases (30y) and controls (18y) due to unequal
number of cases and controls in order to ensure the aver-
age age is similar. The sample size was small and therefore
the associations obtained need to be verified by prospect-
ive follow-up studies including a replication or larger
number of subjects in future.
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